International ‘switch’ expert Natalie Gauld to present at ASMI’s Conference: “S3’s – Is the Australian Consumer Missing Out?”

13 September 2013

Return to Media Release Index

13 September 2013 - The Australian Self Medication Industry (ASMI) has today announced that international 'switch' expert Natalie Gauld will be presenting "Schedule 3 (S3) - Is the Australian Consumer Missing Out?" at this year's conference on Thursday 14 November in Sydney.

Ms Gauld, a pharmacist by background, recently completed a PhD examining why countries vary in prescription to non-prescription reclassification (or switch) of medicines. In-depth interviews with stakeholders in the US, UK, Australia, New Zealand and Japan, and extensive document analysis, showed each country has a unique blend of enablers and barriers to reclassification.
Ms Gauld was the lead author of a study, published last year in the international journal Self Care, which aimed to compare the progressiveness of switch between the Australia and New Zealand and also the UK. The results showed that Australia led "switch innovation" in the early 2000s, but its progressiveness has diminished in recent years.1
According to ASMI Marketing & Business Development Director, Ms Filomena Maiese:
"Natalie Gauld's plenary session at the ASMI Conference is set to deliver a number of critical insights for the consumer healthcare industry. The issue of lifting the current restrictions on S3 communication remains high on ASMI's agenda and is an issue that affects Australian consumers, our members and the broader healthcare community."
For some time, ASMI has been working with the Pharmacy Guild and the Pharmaceutical Society of Australia on an alternative consumer communication model for S3s, which will permit branded communication of certain S3 medicines.

Under the proposed model, the emphasis will be on creating consumer awareness about the condition and/or symptoms for which a particular S3 medicine is indicated, and highlighting the importance of the role of the pharmacist in determining whether themedicine is appropriate for that consumer.

ASMI recently included the proposed S3 Communication model as part of its response to the consultation on the review of the scheduling framework as well as the recent consultation into advertising of therapeutic goods. ASMI also continues to engage with key stakeholders to gain broader support for ASMI's proposed model.

To register for the conference and for the full list of conference speakers and topics, please visit Regular conference updates will be included on Twitter #ASMIconf.

The ASMI Annual General Meeting will precede the conference at 7.30 am. The conference will be followed with the 2013 ASMI Diamond Awards Dinner at 7.00 pm.
Media contact: Michelle Sollitt-Davis - ASMI PR Manager
Ph: 02 9923 9410 | M: 0422 084 951 | Email:

About ASMI: The Australian Self-Medication Industry (ASMI) is the peak industry body for the Australian self care industry representing consumer healthcare products including over-the-counter medicines and complementary medicines. ASMI's mission is to promote better health through responsible self-care. This means ensuring that safe and effective self-care products are readily available to all Australians at a reasonable cost. ASMI works to encourage responsible use by consumers and an increasing role for cost-effective self-medication products as part of the broad national health strategy.

1. Gauld N. Innovations from 'Down-Under': A Focus on Prescription to Non-Prescription Medicine Reclassification in New Zealand & Australia. SelfCare 2012;3(5):88-107
When: Thursday 14 November 2013. Registration and morning tea at 8.30 am
Where: Waterview Convention Centre, Bicentennial Park, Homebush, Sydney
Who: Delegates from all sectors from the consumer healthcare industry are encouraged to attend
How: Register online at
Contact: Claire Johnson, ASMI Member Events and Services Associate
02 9922 5111 |